Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2019-07-23
Target enrollment:
Participant gender:
Summary
A phase 2, multicenter study to evaluate the efficacy and safety of twelve once weekly
subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not
well-controlled by metformin mono therapy.